

Tyrosine Kinase Inhibitors Market Poised for Growth, Expected to Reach \$81.41 Billion by 2028

The Business Research Company's Tyrosine Kinase Inhibitors Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LANDON, GREATER LANDON, UK, July 3, 2024 /EINPresswire.com/ -- The global [tyrosine kinase inhibitors \(TKI\) market](#) has witnessed strong growth in recent years, driven by advancements

in cancer treatment and targeted therapies. The market size is projected to increase from \$53.72 billion in 2023 to \$58.69 billion in 2024, growing at a compound annual growth rate (CAGR) of 9.3%. It will grow to \$81.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%.

This growth can be attributed to key factors such as the discovery of tyrosine kinases, enhanced understanding of cancer signaling pathways, and the clinical success of early TKIs like imatinib (Gleevec).



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs”
*The Business Research
Company*

Rising Prevalence of Cancer Propels Market Growth
The increasing prevalence of cancer globally is a major driver for the growth of the tyrosine kinase inhibitors market. Cancer, characterized by uncontrolled cell growth and spread, underscores the critical need for targeted

therapies that can selectively inhibit cancerous cells while sparing healthy tissues. For instance, the American Cancer Society reported a 3.16% increase in cancer cases from 2021 to 2023, highlighting the growing demand for effective cancer treatments like TKIs.

Explore the global tyrosine kinase inhibitors market with a detailed sample report:
https://www.thebusinessresearchcompany.com/sample_request?id=11957&type=smp

Key Players and Market Trends

Major companies in the tyrosine kinase inhibitors market, including Pfizer Inc., Johnson & Johnson Private Limited, and Novartis AG, are focusing on innovations such as biomarker-driven



therapies and drug delivery advancements. Strategic partnerships, like Mithra Pharmaceuticals SA's collaboration with BCI Pharma to develop novel TKIs, underscore the industry's commitment to expanding treatment options across various cancer types.

Segments

1. Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
2. Distribution Channel: Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
3. Application: Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications

Geographical Insights: North America Leads, Asia-Pacific to Witness Rapid Growth

North America dominated the tyrosine kinase inhibitors market in 2023, driven by robust healthcare infrastructure and high adoption of advanced therapies. However, Asia-Pacific is expected to emerge as the fastest-growing region, supported by increasing healthcare investments and rising awareness of personalized medicine.

Order your report now for swift delivery

<https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report>

Tyrosine Kinase Inhibitors Global Market Report 2024 from TBRC covers the following information:

1. Market size data for the forecast period: Historical and Future
2. Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
3. Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Tyrosine Kinase Inhibitors Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on tyrosine kinase inhibitors market size, tyrosine kinase inhibitors market drivers and trends, tyrosine kinase inhibitors market major players, competitors' revenues, market positioning, and market growth across geographies. The tyrosine kinase inhibitors market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

HER2 Inhibitors Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report>

Protein Inhibitors Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report>

Checkpoint Inhibitors Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report>

[About The Business Research Company](#)

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724789065>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.